The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.
 
Alex A. Adjei
No Relationships to Disclose
 
Grace K. Dy
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); OncoMed (Inst)
 
Yujie Zhao
No Relationships to Disclose
 
Wen Wee Ma
No Relationships to Disclose
 
Mateusz Opyrchal
No Relationships to Disclose
 
Hatoon Bakhribah
No Relationships to Disclose
 
Sandra M Jacob
No Relationships to Disclose
 
Corrie O'Hara
No Relationships to Disclose
 
Askia Dozier
No Relationships to Disclose
 
Natasa Cmiljanovic
Employment - Piqur
 
Barbara Todaro
No Relationships to Disclose
 
William E. Brady
Consulting or Advisory Role - Ultragenyx Pharmaceuticals
Research Funding - Nektar (Inst)
 
Debora Schmitz
Employment - Piqur
 
Sasa Dimitrijevic
Employment - Piqur